Novel staging protocol for non-small-cell lung cancers according to MRP- 1/CD9 and KAI1/CD82 gene expression

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1397-1406

  Adachi, Masashi ^a   Taki, Toshihiko ^a   Konishi, Takaaki ^a   Huang, Cheng Long ^a   Higashiyama, Masahiko ^a   Miyake, Masayuki ^a  

^a Kitano Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC VALUE; FEMALE; GENE EXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL;

EID: 0031923869     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1397     Document Type: Article

References (42)

1. Hart IR, Saini A: Biology of tumor metastasis. Lancet 339:1453-1457, 1992
2. Miyake M, Koyama M, Seno M, et al: Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility. J Exp Med 174:1347-1354, 1991
3. Boucheix C, Benoit P, Frachet P, et al: Molecular cloning of the CD9 antigen. J Biol Chem 266:117-122, 1991
4. Ikeyama S, Koyama M, Yamaoko M, et al: Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med 177:1231-1237, 1993
5. Miyake M, Nakano K, Ieki Y, et al: Motility related protein-1 (MRP-1/CD9) expression: Inverse correlation with metastases in breast cancer. Cancer Res 55:4127-4131, 1995
6. Cajot J, Sordat I, Silvestre T, et al: Differential display cloning identifies Motility-related protein (MRP-1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells. Cancer Res 57:2593-2597, 1997
7. Higashiyama M, Taki T, Ieki Y, et al: Reduced motility-related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small-cell lung cancer. Cancer Res 55:6040-6044, 1995
8. Miyake M, Nakano K, Itoi S, et al: Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res 56:1244-1249, 1996
9. Wright MD, Tomlinson MG: The ins and outs of the transmembrane 4 superfamily. Immunol Today 15:588-594, 1994
10. Scott AF, Elizaga A, Morrell J, et al: Characterization of a gene coamplified with Ki-ras in Y1 murine adrenal carcinoma cells that codes for a putative membrane protein. Genomics 20:227-230, 1994
11. Fitter S, Tetaz TJ, Berndt MC, et al: Molecular cloning of cDNA encoding a novel platelet-endothelial cell tetra-span antigen, PETA-3. Blood 86:1348-1355, 1995
12. Hasegawa H, Utsunomiya Y, Kishimoto K, et al: SFA-1, a novel cellular gene induced by human T-cell leukemia virus type 1, is a member of the transmembrane 4 superfamily. J Virology 70:3258-3263, 1996
13. Dong JT, Lamb PW, Rinker-Schaeffer CW, et al: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268:884-886, 1995
14. Dong JT, Suzuki H, Pin SS, et al: Down-regulation of KAI1 metastasis-suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 56:4387-4390, 1996
15. Ueda T, Ichikawa T, Tamaru J, et al: Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. Am J Pathol 149:1435-1440, 1996
16. Adachi M, Taki T, Ieki Y, et al: Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small-cell lung cancer. Cancer Res 56:1751-1755, 1996
17. Hotta H, Ross AH, Huebner K, et al: Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Cancer Res 48:2955-2962, 1988
18. Radford KJ, Thorne RF, Hersey P: CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with beta-1 integrins in human melanoma. Biochem Biophys Res Com 222:13-18, 1996
19. Imai T, Yoshie O: C33 antigen and M38 antigen recognized by monoclonal antibodies inhibitory to syncytium formation by human T cell leukemia virus type 1 are both members of the transmembrane 4 superfamily and associate with each other and with CD4 or CD8 in T cells. J Immunol 151:6470-6481, 1993
20. Hemler ME, Mannion BA, Berditchevski F: Association of TM4SF proteins with integrins: Relevance to cancer. Biochemica et Biophysica Acta 1287:67-71, 1996
21. Hermanek P, Sobin LH, (eds): TNM Classification of Malignant Tumours (ed 4). Berlin, Germany, Springer-Verlag, 1987, pp 75-80
22. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987
23. Metzelaar MJ, Wigngaard PLJ, Peters PJ, et al: CD63 antigen: A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem 266:3239-3245, 1991
24. Nakajima-Iijima S, Hamada H, Reddy P, et al: Molecular structure of the human cytoplasmic β-actin gene: Interspecies homology of sequences in the introns. Proc Natl Acad Sci USA 82:6133-6137, 1985
25. Takahashi K, Sawasaki Y: Rare spontaneously transformed human endothelial cell line provides useful research tool. In Vitro Cell Dev Biol 28A:380-382, 1992
26. Scheck AC, Mehta BM, Beikman MK, et al: BCNU-resistant human glioma cells with overepresentation of chromosomes 7 and 22 demonstrate increased copy number and expression of platelet-derived growth factor genes. Genes Chromosom Cancer 8:137-148, 1993
27. Coen DM: Quantitation of rare DNAs by PCR, in Ausbel FM, Brent R, Kingston RE, et al (eds): Current Protocols in Molecular Biology. New York, NY, John Wiley & Sons, 1995, pp 15.3.1-15.3.8
28. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
29. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
30. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
31. Statistics and Information Department Vital Statistics 1993 Japan, vol 1. Tokyo, Japan, Ministry of Health and Welfare, 1995, pp 274-279
32. Van Houtte P, Rocmans P, Smets P, et al: Postoperative radiation therapy in lung cancer: A controlled trial after resection of curative design. Int J Radiat Oncol Biol Phys 6:983-986, 1980
33. Niiranen A, Niitamo-Korhonen S, Kouri M, et al: Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: A randomized study. J Clin Oncol 10:1927-1932, 1992
34. Wada H, Hitomi S, Teramatsu T, et al: Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J Clin Oncol 14:1048-1054, 1996
35. Fearon ER, Vogelstein BA: A genetic model of colorectal tumorigenesis. Cell 61:759-761, 1990
36. Slebos RJC, Kibbelaar RE, Dalesio O, et al: K-ras oncogene activation as a poor prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561-565, 1990
37. Rosell R, Li S, Skacel Z, et al: Prognostic impact of mutated K-ras gene in surgically resected non-small-cell lung cancer patients. Oncogene 8:2407-2412, 1993
38. Rabbits P, Douglas J, Daly M. et al: Frequency and extent of allelic loss in the short arm of chromosome 3 in non-small-cell lung cancer. Genes Chromosom Cancer 1:95-105, 1989
39. Mitsudomi T, Steinberg SM, Nau MM, et al: p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171-180, 1992
40. Quinlan DC, Davidson AG, Summers CL, et al: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828-4831, 1992
41. Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in p53 tumor-supressor gene: Clue to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994
42. b antigens with survival in patients with carcinoma of the lung. N Engl J Med 327:14-18, 1992